Incidence and predictors of initial antiretroviral therapy regimen change among children in public health facilities of Bahir Dar City, Northwest Ethiopia, 2021: multicenter retrospective follow-up study

Molla Azmeraw1*, Yinager Workineh2, Frihiwot Girma2, Amare Kassaw3, Gashaw Kerebeh3, Abraham Tsedalu4, Agimasis Tigabu4, Teshale Mengesha5, Eleni Dagnaw6, Dessie Temesgen1, Biruk Beletew1, Getenet Dessie7 and Melsew Dagne1

Abstract

Background: The inconsistent use of antiretroviral therapy can lead to the risk of cross-resistance between drugs. This reduces subsequent antiretroviral drug options. The burden of initial antiretroviral therapy ranges from 11.3% in South Africa to 71.8% in Malaysia. There is evidence that it is important to maintain children's initial antiretroviral therapy regimens. However, the incidence and predictive factors of initial antiretroviral therapy regimen changes in the research context are still unknown in the study setting. So, the study was aimed to assess incidence and predictors of initial antiretroviral therapy regimen changes among children in public health facilities of Bahir Dar city.

Methods: A retrospective follow-up study was conducted in 485 children who received antiretroviral therapy between January 1, 2011 and December 30, 2020. These children were selected using simple random sampling techniques. The data were entered by Epi data 3.1 and the analysis was completed by STATA 14.0. The missing data was treated with multiple imputation method. The data were also summarized by median or mean, interquartile range or standard deviation, proportion and frequency. The survival time was determined using the Kaplan Meier curve. The Cox Proportional Hazard model was fitted to identify predictors of initial antiretroviral therapy regimen change. The global and Schoenfeld graphical proportional hazard tests were checked. Any statistical test was considered significant at P-value < 0.05. Finally, the data were presented in the form of tables, graphics and text.

Result: Among the 459 study participants, 315 of them underwent initial regimen changes during the study accumulation period. The shortest and longest follow up time of the study were 1 month and 118 months, respectively. The overall incidence rate of initial regimen change was 1.85, 95% CI (1.66–2.07) per 100 person-month observation and the median follow up time of 49 (IQR 45, 53) months. The independent predictors of initial regimen changes were poor adherence (AHR = 1.49, 95%CI [1.16, 1.92]), NVP based regimen (AHR = 1.45, 95%CI [1.15, 1.84]) comparing to...
EFV based regimen, LPVr based regimen (AHR = 0.22, 95%CI: (0.07, 0.70)) comparing to EFV based regimen, history of tuberculosis (AHR = 1.59, 95%CI [1.14, 2.23]) and being male (AHR = 1.28, 95%CI [1.02, 1.60]).

Conclusions and recommendations: In this study, the incidence of initial regimen change was high. The risk of initial regimen change would be increased by being male, poor adherence, having history of tuberculosis and NVP based initial regimen. Therefore, strengthening the health care providers’ adherence counseling capability, strengthening tuberculosis screening and prevention strategies and care of initial regimen type choice needs attention in the HIV/AIDS care and treatment programs.

Keywords: Children, Human immunodeficiency virus, Antiretroviral therapy, Initial regimen change, Ethiopia

Background

Although various plans and policies have been implemented in the past 40 years to combat the impact of HIV/AIDS, the current reduction in HIV/AIDS-related morbidity and mortality is also rested on early diagnosis, early initiation and continuous use of antiretroviral therapy. The inconsistent ART use increases the likelihoods of adverse outcomes in HIV care and treatment programs, including treatment failure [1, 2].

Antiretroviral therapy regimen change (ARTRC) refers to the substitution of one or more of the antiretroviral drugs in the initial antiretroviral therapy (ART) regimen. The drugs may belong to the same or different drug classes [3, 4]. If the antiretroviral treatment regimen is changed for the first time, it is called an initial regimen change (IRC). Often, changes in the antiretroviral treatment regimen will occur as long as the child receives HIV treatment and care for a variety of reasons within a few months and beyond. The reasons may be market availability, toxicity, treatment failure, drug stock-out, or simplification [5]. A one or more ART drugs can also be changed from the initial regimen to another regimen, depending on the patient’s condition and recommendations from WHO or specific country guidelines [6]. Before making changes to the patient’s ART regimen, clinicians will consider the patient’s past regimen, past ART failure episodes, past drug resistance test results, drug costs, and the patient’s ability to tolerate the new regimen [7].

The magnitudes of RC varied across the previously conducted studies in children [3, 8, 9]. In America and Malaysia, the prevalence of initial regimen change among children was 72% [8] and 71.8% [3], respectively. Moreover, a randomized trial of PIs and NNRTIs in the United States of America showed that 72% of participants experienced at least one treatment disruption during 8 years of follow up [8]. In Spain, a follow-up study among 212 HIV-infected children also reported that only 24% of children remained on their first combination therapy [10]. In addition, a prospective study in Ghana reported that 33.3% of the participants had experienced initial RC [11]. Another study in South Africa also revealed that overall incidence of initial ARTRC was 85.9 per 1000 patient-years, only 72 and 26% of children were remained on initial regimen at three and 5 years of ART during 10 years of study follow-up, respectively [12]. Another two different studies in South Africa showed that 11.3 and 26% of the study participants experienced IRC [12, 13]. Similarly, 2 years regimen durability study in South Africa revealed that there were about 15.3% single-drug substitutions, 7.2% treatment interruptions and 3.3% switched to second-line therapy [9].

The initial or subsequent RC could be affected by a variety of factors which might vary greatly with baseline laboratory values CD4 count [14], co morbidity [8, 15], initial regimen type [8, 14], having poor adherence [8, 12], the occurrence of adverse drug reaction/toxicity (ADR) [14], treatment failure [8, 12, 14] and availability of new drug [15]. These factors often cause significant morbidity and antiretroviral treatment failure. The predisposing factors were also varying across the findings of the previous studies [3, 12, 14, 16].

A serious confront of ART drug substitution, switching, interruption and discontinuation are the emergences of drug resistance, making future therapeutic interventions ineffective and narrowing the subsequent possible alternatives [17]. Additionally, RC also affects the success of HIV treatment to achieve Joint United Nation Program on HIV/AIDS (UNAIDS) 90-90-90 and 95-95-95 goals [18, 19].

In order to improve success of the initial ART regimen in HIV care and treatment program; optimizing the limited available ART regimens is vital [20]. Several studies done on predictors of first line HIV treatment failure were also reported that ART regimen change is a predictor of the subsequent ART failure [21, 22]. Even though the availability of new drugs has improved the patient acceptance, satisfaction to treatment, and safety profile of new regimens, the definition of the best available starting ART regimen is hindered by the lack of data on the exact impact of long-term durability of initial ART regimens [23]. As a result, the knowledge of how often a combination regimen is changed can be a good substitute marker of the regimen success. Even though several studies have
tried to determine incidence and predictors of initial ARTRC, they were not consistent. So far, there were a limited number of studies on predictors of initial ARTRC among children in Ethiopia.

Therefore, this study aimed to determine incidence and predictors of initial ARTRC among children in public health facilities of Bahir Dar city, Northwest Ethiopia, 2021.

Methods

Study design, period and setting

Institution based retrospective follow-up study was conducted in Bahir Dar city from January 1, 2011 to December 31, 2020. Bahir Dar is the capital city of Amhara regional state located in Northwest Ethiopia and 565 km far from Addis Ababa, the capital city of Ethiopia. It also covers an area of 28,000 km² and situated 1,800 m above sea level. The current projected population estimation is 389,177. Of these, 147,983 are children under the age of 15 years. The city administration has three public hospitals and 10 health centers. Pediatric antiretroviral therapy services have been delivered in all public health facilities except Zegie health center in the city. Zegie health center have been provided only prevention of mother to child HIV transmission treatment service. Furthermore, Tibebe Ghion Specialized Comprehensive Hospital and Meshenti health center have no cases on ART under the age of 15 years. So, the study population was from the rest 10 health facilities. In the last 10 years, from January 1, 2011 to December 31, 2020, 747 HIV positive children had been enrolled in ART centers of the study area.

Population

All HIV positive children aged below 15 who were enrolled in all public health facilities of HIV care and treatment centers in Bahir Dar City from January 1, 2011 to December 31, 2020 were the study population. All HIV positive children aged below 15 who started ART in all public health facilities of HIV care and treatment centers in Bahir Dar City from January 1, 2011 to December 31, 2020 were included where as all participants who were transferred in and who had only one visit were excluded.

Variables

Time to initial ART regimen change was the dependent variable. The independent variables were age, sex, parental aliveness, primary care giver HIV status, primary care giver, primary HIV confirming service area, catchment area, base line CD4 count, base line hemoglobin, base line nutritional status, base line functional status, base line opportunistic infection, base line weight, previous exposure for ART drugs, initial regimen, drug class, history of poor adherence, history of tuberculosis, WHO clinical stage deterioration history.

Sample size determination

The sample size was determined using the double population proportion difference formula using Epi Info version 7 software by considering the major predictor variables were regimen type, WHO immunological status and adherence from previously conducted studies in South Africa, Malaysia Europe and Thailand [9, 14, 15]. From those predictor variables, the sample size that we obtained from WHO immunological status had given the final sample size of the study. It gave maximum sample size when compared to other predictors. A proportion of exposed (23%) and non-exposed (16%), one to one exposed to non-exposed ratio (1:1), 95% level of confidence interval, 1.26 hazard ratio and power of 80% was yielded the largest estimated sample size, 1060 individual charts. Then, the largest calculated sample size, 1060 was larger than the reference population. So, correction formula was required.

Let, \( n_1 \) = the calculated sample size, \( N \) = the population, and \( n \) = the final required sample size.

\[
\frac{\text{min} \left( \frac{\text{N}}{\text{N} + 1} \right), \frac{1060}{1 + (1060/1060) \times 0.1} \right)}{\subset 442}, \text{then 10% contingency for incomplete charts was considered.}
\]

Finally, the minimum required sample size was 485.

Sampling technique and sampling procedure

All public hospitals and health centers in Bahir Dar city that has provided ART services were included in the study. Initially, list of the medical record numbers of the children in each ART clinics was prepared. Then, the lists of medical record numbers from all ART clinics were combined to make a single sample frame from the electronic data base (smart care) of each facility. Finally, the study participants were selected through computer generated random number (Fig. 1).

Data collection tool and procedures

In order to collect the data from charts, the structured questionnaire was prepared. The questionnaire was adapted from the Ethiopian Federal Ministry of Health HIV/AIDS care and treatment follow-up forms. The laboratory requests and history sheet documentation were also considered in preparing the questionnaire. Then, data were collected from both patient charts and electronic data base in terms of socio-demographic variables, base line Clinical and laboratory related factors and treatment-related factors of HIV infected children. Charts were accessed based on their medical record numbers. One data clerk personnel for 1 day and two card room workers during the data collection period were recruited. The data were collected by three BSc nurses who are
working at HIV care and treatment clinics from Han health center, Abay health center and Adis alem primary hospital. The supervision was done by both supervisor and principal investigator.

Data quality assurance
Before the data collection, a pretest was done among 25 medical records of children enrolled on ART from year January 1, 2011-December 30, 2020 at Han health center and Felege hiwot comprehensive specialized hospital. Data quality was also guaranteed with a proper recruitment and training of data collectors. The two data collectors have basic comprehensive HIV care and treatment training and the rest one data collector has also ART mentoring certificate. Two supervisors closely supervised the data collection process every day. At the end of each data collection date, the data completeness and consistency was cross-checked by supervisor and principal investigator. In addition, once the data were extracted from patient charts, the charts were coded to avoid duplication.

Data processing and analysis
After the data extracted from the charts, it were checked for consistency and completeness. Then, data were coded and entered into Epi Data version 3.1. Next, they were exported to STATA version 14.0 and cleaned. The mean with standard deviation in the case of normally distributed variables, otherwise median with inter-quartile range (IQR) were used as descriptive and summary statistics for continuous variables. Frequencies and proportions were also used to describe the characteristics of categorical variables. The missing data was handled via multiple imputations for CD4 count and hemoglobin level. Kaplan–Meier survival curve was used to estimate median time. The incidence of initial ART regimen change during the follow up period was calculated and presented as per 100 person month’s observation. Cox Proportional Hazards regression model fitness was checked by using Shoenfeld residuals test (global test) together with graphical test. The assumptions were met for both tests. In addition, the overall goodness of model fitness was checked via Cox Snell residual. The Nelson Aalen hazard function follows the 45° line very closely except for very large values of time. So, it can be concluded that the final model fits very well.

Then, the bivariable analysis was done to identify associations between dependent and each independent variable.
Variables with $P \leq 0.25$ levels in the bivariable analysis were considered as candidate variable to be entered into the multivariable analysis. The multi co linearity of the candidate variables was checked using Cramer’s V correlation coefficient. Adjusted hazard ratio, 95% CI and $P$-value was used to assess the strength of association and statistical significance. Any statistical test was considered significant at $P$-value < 0.05.

Operational definitions
In this study, event was occurrence of initial ART regimen change. Initial ART regimen change defined as either first-time substitution of at least one drug from the original regimen within or out of the drug class including complete switch of the entire regimen. Time-to-event (ART regimen change) was calculated by subtracting the date of antiretroviral therapy (ART) regimen initiation from the date of the event occurred or censored. Survival status was the outcome of children; either ART regimen changed or censored. Patients with the first date of lost to follow up, defaulters, transfer out, death before the end of the follow-up period and completed the follow-up period without developing the event was considered as censored. Date of ART initiation (month “0”) and date of initial regimen change or censoring was used as starting and end time of study follow up, respectively. In addition, month was used as measurement scale. Regarding to chart incompleteness, the chart is said to be incomplete when there was unknown outcome status and/or unknown ART initiation date.

Result
Socio-demographic related characteristics
Among 485 participants, 459 were included for analysis. About 315 (68.63%) of them undergone first-line antiretroviral therapy regimen changes. Of which 91.11% ($n = 287$) were undergone drug substitution and the rest 28(8.89%), 95%CI (27.28, 35.78) were switched to second-line ART regimen. The socio-demographic characteristics of the participants were summarized below (Table 1).

Base line clinical, laboratory and treatment related characteristics
Base line clinical, laboratory and treatment related characteristics of the participants were summarized (Table 2).

Regimen combinations and outcomes
Majority of the ART drug combinations (93.9%) were non nucleotide reverse transcriptase inhibitors based (NNRTI) and the rest 5.23 and 0.87% were protease inhibitor based and integrase strand inhibitor based regimen, respectively. The initial regimens were AZT/3TC/NVP (35.1%), AZT/3TC/EFV (22.7%), D4T/3TC/NVP (16.3%), TDF/3TC/EFV (7.63%), ABC/3TC/LPVr (5.01%), D4T/3TC/EFV (4.14%), TDF/3TC/DTG (0.2%), ABC/3TC/DTG (0.9%) and other regimens (9.12%).

| Variables                          | Categories               | Censored n (%) | Initial regimen change n (%) |
|------------------------------------|--------------------------|----------------|-------------------------------|
| Age                                | ≤36 months               | 41(41.41)      | 58(58.59)                     |
|                                   | > 36 months              | 103(28.61)     | 257(71.39)                    |
| Sex                                | Male                     | 70(28.57)      | 175(71.43)                    |
|                                   | Female                   | 74(34.58)      | 140(65.42)                    |
| Parental aliveness                 | One or both parent       | 138(31.15)     | 305(68.85)                    |
|                                   | Both died                | 6(3.45)        | 10(62.50)                     |
| Primary care giver                 | Parent                   | 126(30.07)     | 293(69.93)                    |
|                                   | Non-parent               | 18(45.00)      | 22(55.00)                     |
| Primary care giver HIV status      | Positive                 | 118(29.87)     | 277(70.13)                    |
|                                   | Negative or unknown      | 26(40.63)      | 38(59.37)                     |
| Primary HIV confirming services    | PMTCT                    | 26(40.63)      | 38(59.37)                     |
|                                   | Non-PMTCT                | 118(29.87)     | 277(70.13)                    |
| Previous ART drugs exposure        | Yes                      | 25(43.10)      | 33(56.90)                     |
|                                   | No                       | 119(29.68)     | 282(70.32)                    |
| Catchment residence                | Yes                      | 111(30.41)     | 254(69.59)                    |
|                                   | No                       | 33(35.11)      | 61(64.89)                     |

Hint: ART-antiretroviral therapy, HIV human immunodeficiency virus, PMTCT Prevention of mother to child transmission
Among the study participants, the ART outcomes during the follow-up time were regimen change (68.63%), transfer out (16.56%), on follow-up (11.98%), died (1.74%) and lost to follow-up (1.09%).

Incidence and survivorship status of initial regimen change

The overall incidence rate of initial regimen change was 1.85, 95% CI (1.66, 2.07) per 100 PMO over a total of 17,010 person-months of follow-up. The overall median survival time was also 49 months, 95%CI (45, 53). The shortest and longest follow-up time was 1 month and 118 months, respectively. The Kaplan- Meier estimation showed that overall estimated survival on initial regimen after starting ART was about 90% at 6 months of follow up. The estimated cumulative survival on initial regimen at 6, 12, 24, 36, 60 months and end of follow-up were 90, 84, 70, 61, 32 and 3%, respectively as showed in Kaplan- Meier survival estimate curve (Fig. 2).

| Variables                         | Categories                        | Censored, n (%) | Initial regimen change, n (%) |
|-----------------------------------|-----------------------------------|----------------|-----------------------------|
| Opportunistic infection           | Yes                               | 73(29.92)      | 171(70.08)                  |
|                                   | No                                | 71(33.02)      | 144(66.98)                  |
| Functional status                 | No or mild limitation             | 121(31.84)     | 259(68.16)                  |
|                                   | Moderate or severe limitation     | 23(29.11)      | 56(70.89)                   |
| CD4 count                         | ≤200 cells/m³                     | 19(35.19)      | 35(64.81)                   |
|                                   | > 200 cells/m³                    | 125(30.86)     | 280(69.14)                  |
| Weight                            | ≤20 kg                            | 88(32.47)      | 136(67.53)                  |
|                                   | > 20 kg                           | 56(29.79)      | 132(70.21)                  |
| Serum hemoglobin                  | ≤11 mg/dl                        | 26(40.63)      | 38(59.38)                   |
|                                   | > 11 mg/dl                        | 118(39.87)     | 277(60.13)                  |
| History tuberculosis              | Yes                               | 11(21.15)      | 41(78.85)                   |
|                                   | No                                | 133(32.68)     | 274(67.32)                  |
| ART regimen                       | TDF based                         | 12(30.00)      | 28(70.00)                   |
|                                   | ABC based                         | 35(60.34)      | 23(39.66)                   |
|                                   | AZT based                         | 81(30.34)      | 186(69.66)                  |
|                                   | D4T based                         | 16(17.02)      | 78(82.98)                   |
| Deterioration of WHO clinical stage| Yes                              | 25(75.00)      | 7(25.00)                    |
|                                   | No                                | 142(31.49)     | 309(68.51)                  |
| Adherence                         | Good                              | 129(36.54)     | 224(63.46)                  |
|                                   | Poor/fair                         | 15(4.15)       | 298(95.85)                  |
| ART regimens                      | NVP based                         | 62(24.41)      | 192(75.59)                  |
|                                   | EFV based                         | 55(31.61)      | 119(68.39)                  |
|                                   | DTG based                         | 5(83.33)       | 1(16.67)                    |
|                                   | LPVr based                        | 22(88.00)      | 3(12.00)                    |
| Nutritional status                | Severe and moderate under nutrition| 55(26.44)    | 153(73.56)                  |
|                                   | Normal and mild under nutrition    | 89(35.46)      | 162(64.54)                  |

*Hint* WHO-world health organization, NVP Nevirapine, EFV Efavirenz, DTG Dolutegravir, LPVr Lopinavir, ART antiretroviral therapy

Incidence rate and median survival time of initial regimen change per groups of variables is summarized below (Table 3).

Predictors of initial ART regimen change

In the multi variable Cox regression analysis, sex, adherence, history of TB and regimen type found to be predictors of initial regimen change (Table 4). In this regard, children who had history of poor or fair adherence of ART were 49% more likely to develop initial regimen change as compared to those who had history of good adherence (AHR =1.49, 95%CI: (1.16, 1.92)). The hazard of initial regimen change among children who had history of TB were 59% more likely as compared to the counter parts (AHR =1.59, 95%CI: (1.14, 2.23)). In addition, those children initiated ART with NVP regimen at base line were 45% more likely to develop initial regimen change as compared to EFV based regimen (AHR =1.45, 95%CI:(1.15, 1.84)). Moreover, those children on

Table 2 Base line characteristics of HIV positive children at ART initiation in public health facilities of Bahir Dar city, Northwest Ethiopia, 2021(N = 459)
ART who initiated LPVr based regimen were 78% less likely to change their initial regimen as compared to those children who initiate ART with EFV based regimen (AHR = 0.22, 95%CI: (0.07, 0.70)).

The adjusted hazard of being male for initial regimen change was 1.28 times more likely as compared to being female (AHR = 1.28, 95%CI: (1.02, 1.60)).

**Discussion**

This retrospective follow-up study was aimed to determine the incidence and predictors of initial ART regimen change in Bahir Dar city, Ethiopia. Based on this objective, the overall incidence of initial ART regimen change was 1.85 per 100 PMO which were predicted by adherence level, regimen type, tuberculosis and sex of child. The incidence rate was higher than study done in sub Saharan Africa (0.41 per 100 PMO) [16] and Mali (0.28 per 100 PMO [24]. The discrepancy could be due to studies in sub Saharan Africa and Mali were about only switching to second-line ART but this study included both drug substitution and switching to second-line regimen. Furthermore, treatment failure had been diagnosed through the level of CD4 count and WHO clinical stage in the earlier years of HIV care and treatment especially in developing countries but currently, WHO recommends routine viral load test which is important for early diagnosis of treatment failure to meet the 95–95–95 UNAIDS goals [25, 26]. As the finding of this study revealed, the clinicians need to careful for their practice of individual regimen management whether they have been adhered to standards and evidence-based practice.

**Fig. 2** Kaplan-Meier curve estimate of overall survival status of children on initial regimen in public health facilities of Bahir Dar city, Northwest Ethiopia, 2021

**Table 3** Incidence rate and median survival time of initial regimen change per groups of variables among children in public health facilities of Bahir Dar city, Northwest Ethiopia, 2021 (N = 459)

| Variables               | Categories | IR of IRC per 100 PMO | Median (IQR) |
|-------------------------|------------|------------------------|--------------|
| Sex                     | Male       | 1.95(1.68, 2.26)       | 46(37, 52)   |
|                         | Female     | 1.75(1.48, 2.06)       | 52(45, 57)   |
| History tuberculosis    | Yes        | 2.48(1.82, 3.36)       | 34(17, 52)   |
|                         | No         | 1.78(1.59 2.01)        | 50(45, 54)   |
| Adherence               | Good       | 1.66(1.46,1.90)        | 57(46, 56)   |
|                         | Poor/fair  | 2.57(2.09, 3.15)       | 37(25, 47)   |
| ART drug regimen        | ABC/3TC/EFV| 1.89(1.05,3.41)        | 43(19, 60)   |
|                         | AZT/3TC/EFV| 1.37(1.07, 1.73)       | 54(50, 64)   |
|                         | AZT/3TC/NVP| 1.79(1.49, 2.14)       | 57(53, 59)   |
|                         | TDF/3TC/EFV| 1.68(1.12, 2.50)       | 47(33, 56)   |
|                         | ABC/3TC/NVP| 2.11(1.14, 3.93)       | 25(18, 46)   |
|                         | D4T/3TC/NVP| 3.39(2.64, 4.36)       | 22(13,33)    |
|                         | D4T/3TC/EFV| 3.26(2.02, 5.24)       | 17(13, 28)   |

Kaplan-Meier survival estimate, overall

| Variables               | Categories | IR of IRC per 100 PMO | Median (IQR) |
|-------------------------|------------|------------------------|--------------|
| Sex                     | Male       | 1.95(1.68, 2.26)       | 46(37, 52)   |
|                         | Female     | 1.75(1.48, 2.06)       | 52(45, 57)   |
| History tuberculosis    | Yes        | 2.48(1.82, 3.36)       | 34(17, 52)   |
|                         | No         | 1.78(1.59 2.01)        | 50(45, 54)   |
| Adherence               | Good       | 1.66(1.46,1.90)        | 57(46, 56)   |
|                         | Poor/fair  | 2.57(2.09, 3.15)       | 37(25, 47)   |
| ART drug regimen        | ABC/3TC/EFV| 1.89(1.05,3.41)        | 43(19, 60)   |
|                         | AZT/3TC/EFV| 1.37(1.07, 1.73)       | 54(50, 64)   |
|                         | AZT/3TC/NVP| 1.79(1.49, 2.14)       | 57(53, 59)   |
|                         | TDF/3TC/EFV| 1.68(1.12, 2.50)       | 47(33, 56)   |
|                         | ABC/3TC/NVP| 2.11(1.14, 3.93)       | 25(18, 46)   |
|                         | D4T/3TC/NVP| 3.39(2.64, 4.36)       | 22(13,33)    |
|                         | D4T/3TC/EFV| 3.26(2.02, 5.24)       | 17(13, 28)   |
along with the national guideline while changing the regi-
mens or not.

The finding of this study showed that the hazard of initial regimen change among children who initiate NVP based regimen was higher than those children who initiated EFV based ART regimen. The finding was supported by large sample study in France [27] and multicenter study in Europe and Thailand [14]. This risk difference might be due to NVP toxicity. NVP toxicity is associated with immune competency results in NVP based regimen to have higher regimen change rate [28]. This could be after WHO recommendations of ART initiation regardless of CD4 count in children [29]. In addition, the finding was deferred from the study done in Malaysia which stated that NNRTI based categories of regimen had no difference for regimen change [3]. This could be due to sample size and analysis model used by this study. The risk of regimen change difference between NVP and EFV based regimens could be due to the adverse effect of EFV more frequently occur within months and self-resolved without regimen change within months. Additionally, EFV has high half life than NVP which result in low frequency of daily dose and good adherence [30]. Besides, the hazard difference between these drugs could be due to the CD4 dependent serious side effect of NVP and its self inducing characteristics of its metabolism [30]. The other hazard difference between the two groups might be due to the high barrier resistance of EFV and its viral suppressing effect over NVP [31]. On the other hand, those children who started LPVr based regimen had lower hazard of initial regimen change than EFV based regimens which is consistent with study done in Thailand [14]. This could partly mirror the reluctance of clinicians to switch children failing LPVr based regimen due to the difficulty in deciding what to switch to, and recommendations to first address adherence issues due to the high resistance barrier and guideline restriction for children aged less than 3 years [26, 32]. This implies that LPVr based regimen is preferable than EFV and NVP based regimens to advance the potential durability of the initial regimen which supports the current WHO recommendation of ARV drug preference lists.

In this study, the hazard of initial regimen change among children who had poor adherence was higher than those children who had good adherence. The finding was similar with the study done in Malaysia [3]. The hazard difference between the two groups could be due to immature disclosure especially in old children. In addition, palatability and preparation of the drugs might be lead to poor adherence in this age group. Similarly, frequency of dosing, drug side effects, child’s age and development stage, psychosocial, behavioral, and socio-demographic characteristics of children and caregivers might be associated with poor adherence [33]. Furthermore, infants and children are dependent on others for medication administration. As a result adult caregivers may face barriers that contribute to poor adherence in children including forgetting doses, changes in routine, being too busy, and child refusal [34]. This finding showed that despite the current strategies to boost ART adherence practice of the child,

| Variables                          | Categories | Censored n (%) | IRC (event) n (%) | CHR (95%CI) | AHR (95%CI) | P-value |
|-----------------------------------|------------|----------------|-------------------|-------------|-------------|---------|
| Sex                               | Male       | 70(28.57)      | 175(71.43)        | 1.14(.92,1.43) | 1.28(1.02, 1.60) | .03     |
|                                   | Female     | 74(34.58)      | 140(65.42)        | 1           | 1           | .       |
| Functional status                 | No limitation | 121(31.84)   | 259(68.16)        | 1           | 1           | .       |
|                                   | Moderate or severe limitation | 23(29.11) | 56(70.89)        | 1.31(.98,1.75) | 1.30(.97, 1.74) | .079    |
| History tuberculosis             | Yes        | 11(21.15)      | 41(78.85)         | 1.46(1.05,2.03) | 1.59(1.14,2.23) | .007    |
|                                   | No         | 133(32.68)     | 274(67.32)        | 1           | 1           | .       |
| WHO clinical stage deterioration  | Yes        | 2(25.00)       | 6(75.00)          | 1.78(0.97,4.00) | 1.69(0.74, 3.83) | .210    |
|                                   | No         | 142(31.49)     | 309(68.51)        | 1           | 1           | .       |
| Adherence                         | Good       | 129(36.54)     | 224(63.46)        | 1           | 1           | .       |
|                                   | Poor/fair  | 15(14.15)      | 91(85.85)         | 1.52(1.2,1.95) | 1.49(1.16, 1.92) | .002    |
| ART drug regimen                  | NVP based  | 62(24.41)      | 192(75.59)        | 1.32(1.05,1.66) | 1.45(1.15, 1.84) | .002    |
|                                   | EFV based  | 55(31.61)      | 119(68.39)        | 1           | 1           | .       |
|                                   | DTG based  | 5(83.33)       | 1(16.67)          | 0.99(0.14,7.2) | 3.45(0.5, 2.54) | .296    |
|                                   | LPVr based | 22(88.00)      | 3(12.00)          | 0.38(12,1.12) | 2.24(0.7, 7.0) | .011    |

Hint DTG-Dolutegravir, EFV Efavirenz, IRC initial regimen change, LPV Lopinavir, NVP Nevirapine
adherence is still challenging in clinical practice of HIV care and treatment program.

This study finding also showed that hazard of initial ART regimen change was higher for being male than being female. The finding was comparable with an international cohort collaboration regimen change study reported that male had higher rate of switching to second line regimen over female [35] and the Pediatric International Epidemiology Databases to Evaluate AIDS (IeDEA) study member countries (Asia-pacific and African countries) [36]. The gender discrepancy might be due to psychosocial transition difference. In addition, sex discrepancies in treatment outcomes are thought to result from differences in both biologic and behavioral factors including antiretroviral metabolism, antiretroviral adherence and retention in care. A related study on sex difference in pharmacologic effect of antiretroviral therapy among adult reported that sex-related variations in the expression and activities of drug transporter genes, proteins, and enzymes involved in phases of the drugs biotransformation [37]. The difference in maintaining initial ART regimen between male and female child implies the requirement of further close supervision for male child by clinicians and other responsible bodies.

Moreover, the finding of this study revealed that the hazard of initial regimen change among children who has history of tuberculosis was higher than those children who hadn't history of tuberculosis. The finding was consistent with studies conducted in Ghana [11] and Uganda [38]. The hazard difference between the two groups could be due to the occurrences of adverse effect of ART drugs together with the extra dose frequencies of both drugs (ART and anti-TB) which lead to poor adherence [39, 40]. In addition, TB-HIV co infection may impair or delay immune recovery after ART initiations. Furthermore, TB is the most frequent life-threatening opportunistic infection and the leading cause of death among HIV positive children [5]. TB speeds up the viral replication in HIV infected individuals which in turn leads to treatment failure due to ineffective antiretroviral drugs [26]. In addition, the initial ART regimen could be changed due to drug-drug interaction in children who developed tuberculosis while they were on ART [41].

Since the data were collected from secondary source, some important predictors such as family’s wealth index, viral load at baseline and care giver educational level were missed. Additionally, it also missed some important variables like laboratory diagnostic tests (blood chemistry, organ function test) and some socio-economic factors. Furthermore, it might be prone for selection bias. Another limitation of this study could be over estimation of incidence of initial ART regimen change due to inclusion of all ART regimen changes following national guideline changes.

Conclusions
In a conclusion, the incidence of initial regimen change was high as compared to the previous studies. The possibility of initial regimen change is predicted for HIV positive children who had initiated ART with history of tuberculosis, NVP based regimen, being male by sex and poor adherence. LPVr based regimen is preferable than EFV and NVP based regimens to advance the potential durability of the initial regimen which supports the current WHO recommendation of ARV drug preference lists. Therefore, strengthening the health care providers’ adherence counseling capability, strengthening tuberculosis screening and prevention strategies and care of initial regimen type choice needs attention in the HIV/AIDS care and treatment programs. Moreover, further prospective study is recommended to be conducted by including family’s wealth index, viral load at baseline, care giver educational level, hepatic function test and renal function test.

Abbreviations
ABC: Abacavir; ADR: Adverse Drug Reaction; AIDS: Acquired ImmuneDeficiency Syndrome; ART: Anti Retroviral Therapy; ARTRC: Anti Retroviral Therapy Regimen Change; AZT: Azithymidine/zidovudine; CD4: Cluster of differentiation 4 helper cell; CI: Confidence Interval; D4T: Stavudine; EFV: Efavirenz; HAART: Highly Active Anti Retroviral Therapy; HIV: Human Immunodeficiency Virus; LPV/r: Ritonavir boosted Lopinavir; NVP: Nevirapine; PMO: Person month observation; RC: Regimen Change; TB: Tuberculosis; TDF: Tenofovir; TDF: Tenofovir Disproxil Fumarate; UNAIDS: Joint United Nations Program on HIV/AIDS; WHO: World Health Organization; 3TC: Lamivudine.

Acknowledgments
The authors’ initial thankfulness goes to Bahir Dar University, College of Medicine and Health Sciences Institutional Review Board (IRB) for its ethical approval. Next, our special thanks extended to all data clerk personnel, staff members and administrative officers of each respective health facilities for their unreserved cooperation to provide the requested data. Last but not least, our gratitude and heartfelt thanks extend towards data collectors and supervisor for their valuable contribution to the success of this study.

Authors’ contributions
MAB contributed for conception of this study; MA, FG and YW involved in designing the methodology; develop the tool, data analysis and data interpretation. MA, FG, YW, AK, AT, AT, ED, TM, DT, MD and GK reviewed the methodology and the first draft of the manuscript. YW, GD and BB provide critical revision of the manuscript. All the authors reviewed and approved the final draft of the manuscript.

Funding
There is no funding for this research.

Availability of the data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author (MAB) on reasonable request.
Declarations

Ethics approval and consent to participate
Ethical clearance was obtained from Bahir Dar University, College of Medicine and Health Sciences, ethical clearance was obtained from the Ethics committee (Bahir Dar University, College of Medicine and Health Sciences Institutional Review Board). Then, the data were collected after getting a support letter from the administrative bodies of each health institution. This study did not expose HIV-infected children to unnecessary risk due to reviewing their medical records. Confidentiality was kept at all levels of the study. The data was also used only for this study purpose. The study was carried out according to the Declaration of Helsinki’s relevant guidelines and regulations.

Consent for publication
Not applicable.

Competing interests
The authors declared that they have no conflicts of interest.

Author details
1 Department of Nursing, College of Health Sciences, Woldia University, P. O. Box: 400, Woldia, Ethiopia. 2 Department of Pediatrics and Child Health Nursing, College of Medicine and Health Science, Bahir Dar University, Bahir Dar, Ethiopia. 3 Department of Pediatrics and Child Health Nursing, College of Medicine and Health Science, Debre Tabor University, Debre Tabor, Ethiopia. 4 Department of adult Health Nursing, College of Medicine and Health Science, Debre Tabor University, Debre Tabor, Ethiopia. 5 Department of Pediatrics and Child Health Nursing, College of Health Science, Dire Dawa University, Dire Dawa, Ethiopia. 6 Department of Pediatrics and Child Health Nursing, College of Medicine and Health Science, Debre Birhan University, Debre Birhan, Ethiopia. 7 Department of Adult Health Nursing, College of Medicine and Health Science, Bahir Dar University, Bahir Dar, Ethiopia.

Received: 8 October 2021 Accepted: 28 March 2022
Published online: 08 April 2022

References

1. Harden VA, Fauzi A. AIDS at 30: a history. Potomac books, Inc.; 2012.
2. World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. 2017.
3. Low YS, Ihsahudin F, Razali KAM, Adnan S. Modification of initial highly active antiretroviral therapy (HAART) regimen in Paediatric HIV patients. Open AIDS J. 2018;12:111.
4. Takvua SG, Louvaghe G, Zuma K, Okello V. Durability of first line antiretroviral therapy: reasons and predictive factors for modifications in a Swaziland cohort, 2012.
5. World Health Organization. World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. World Health Organization. https://apps.who.int/iris/handle/10665/260233. License: CC BY-NC-SA 3.0 IGO. World Health Organization. 2018.
6. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach: World Health Organization; 2016. https://www.who.int/publications/i/item/9789241549684.
7. Modifying Antiretroviral Regimens in Children with Sustained Virologic Suppression on Antiretroviral Therapy [Internet]. April 07, 2021. Available from: https://clinicalinfo.hiv.gov/en/guidelines/ pediatric-arr/ modifying-antiretroviral-regimens-children-sustained-virologic-suppression/view= full.
8. Yin DE, Ludema C, Cole SR, Golin CE, Miller WC, Warshaw MG, et al. Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors. PLoS One. 2020;15(11):e0242405.
9. Bonavitz R. Regimen durability in HIV-positive children and adolescents initiating first-line art in a large public sector HIV cohort in. South Africa: Boston University, 2018.
10. Guillén S, Ramos JT, Resino R, Bellón JM, Muñoz MA. Impact on weight and height with the use of HAART in HIV-infected children. Pediatr Infect Dis J. 2007;26(4):334–8.
11. Barry Q, Powell J, Renner L, Bonney EY, Prin M, Ampofo W, et al. Effectiveness of first-line antiretroviral therapy and correlates of longitudinal changes in CD4 and viral load among HIV-infected children in Ghana. BMC Infect Dis. 2013;13(1):476.
12. Fortun-de Smit M, de Waal R, Cohen K, Technau K-G, Stinson K, Maartens G, et al. First-line antiretroviral drug discontinuations in children. PLoS One. 2017;12(2):e0169762.
13. Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr. 2007;7(1):13.
14. Goetgheluer T, Hainaut M, Van der Kelen E, Delforge M, Warszawski J, Le Chenadec J, et al. Time to switch to second-line antiretroviral therapy in children with human immunodeficiency virus in Europe and Thailand. Clin Infect Dis. 2018;66(4):594–603.
15. Desmonde S, Eboa FT, Malateste K, Dicko F, Kouëlvi OK, Ngbeché S, et al. Determinants of durability of first-line antiretroviral therapy regimen and time from first-line failure to second-line antiretroviral therapy initiation among HIV-infected children. AIDS (London, England). 2015;29(12):1527.
16. Palombi L, Marazzi MC, Guidotti G, Germano P, Buonomo E, Scarcella P, et al. Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral-treated patients in sub-Saharan African sites with comprehensive monitoring availability. Clin Infect Dis. 2009;48(1):115–22.
17. Olem D, Sharp KA, Taylor JM, Johnson MO. Overcoming barriers to HIV treatment adherence: a brief cognitive behavioral intervention for HIV-positive adults on antiretroviral treatment. Cogn Behav Pract. 2014;21(2):206–23.
18. Davies M-A, Pinto J. Targeting 90–90–90–don’t leave children and adolescents behind. J Int AIDS Soc. 2015;18(Suppl 6):20745.
19. Joint United Nations Programme on HIV/AIDS (UNAIDS). Fast-Track: ending the AIDS epidemic by 2030. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS), 2014. Report No.: JC2686.
20. Oreil C, Harling G, Lawn SD, Kaplan R, McNally M, Bekker L-G, et al. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther. 2007;12(1):183.
21. Bacha T, Tilahun W, Worku A. Predictors of treatment failure and time to detection and switching in HIV-infected Ethiopian children receiving first-line antiretroviral therapy. BMC Infect Dis. 2012;12(1):197.
22. Sisay MM, Ayale TA, Gelaw YA, Tsegaye AT, Gelaye KA, Melak MF. Incidence and risk factors of first-line antiretroviral treatment failure among human immunodeficiency virus-infected children in Amhara regional state, Ethiopia: a retrospective follow-up study. BMJ Open. 2018;8(4):e019181.
23. Blanco J, Clotet B. Learning from drug changes in antiretroviral therapy. Aids. 2013;27(5):833–4.
24. Landier J, Akonde A, Pizzocolo C, Haïdara I, Drabo M, Pizarro L, et al. Switch to second-line ART in west African routine care: incidence and reasons for switching. AIDS Care. 2011;23(1):75–8.
25. Chapter 1: Advancing towards the three zeros [Internet]. 2020 [cited 2011/11/26]. Available from: https://aids2020.unaids.org/chapter/chapt er-1-advancing-towards-the-three-zeros/.
26. Ethiopian Federal Ministry Of Health, National Consolidated Guidelines For Comprehensive HIV Prevention, Care and Treatment [Internet]. 2018 [cited August]. Available from: https://www.humanitarianresponse.info/en/operations/ethiopia/document/national-comprehensive-hiv-care-guideline-2018.
27. de Bossieu P, Dramé M, Raffi F, Cabie A, Poizot-Martin I, Cotte L, et al. Long-term efficacy and toxicity of abacavir/ lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide cohort study. Medicine. 2016;95(37):e4890.
28. Caixas A, Antunes AM, Marinho AT, Godinho AL, Grilo NM, Marques MM, et al. Evidence for nevirapine bioactivation in man: searching for the first step in the mechanism of nevirapine toxicity. Toxicology. 2012;301(1–3):33–9.
29. World Health Organization. Antiretroviral therapy of HIV infection in infants and children: towards universal access: recommendations for a public health approach-2010 revision: World Health Organization; 2010.

30. Pau AK, George JM. Antiretroviral therapy: current drugs. Infect Dis Clin. 2014;28(3):371–402.

31. Group NAS. Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1. N Engl J Med. 2019;381(9):816–26.

32. World health organization, editor. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed: World Health Organization; 2016.

33. Adherence to Antiretroviral Therapy in Children and Adolescents with HIV [Internet]. 2021. Available from: https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/adherence-antiretroviral-therapy-children-and-adolescents-living-hiv.

34. Skovdal M, Campbell C, Madanhire C, Nyamukapa C, Gregson S. Challenges faced by elderly guardians in sustaining the adherence to antiretroviral therapy in HIV-infected children in Zimbabwe. AIDS Care. 2011;23(8):957–64.

35. Collins U, Wools-Kaloustian K, Goodall R, Smith C, Abrams EJ, Ben-Farhat J, et al. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration. Lancet HIV. 2019;6(2):e105–e15.

36. Wools-Kaloustian K, Marete I, Ayaya S, Sohn AH, Van Nguyen L, Li S, et al. Time to first-line ART failure and time to second-line ART switch in the IeDEA pediatric cohort. J Acquir Immune Defic Syndr. 2018;78(2):221.

37. Ofotokun I, Pomero C. Sex differences in adverse reactions to antiretroviral drugs. Top HIV Med. 2003;11:55–9.

38. Costenaro P, Penazzato M, Lundin R, Rossi G, Massavon W, Patel D, et al. Predictors of treatment failure in HIV-positive children receiving combination antiretroviral therapy: cohort data from Mozambique and Uganda. J Pediatr Infect Dis Soc. 2015;4(1):39–48.

39. Chatterjee S, Bose SS, Khuntdar B, Bhattacharya S. Are first line antiretroviral therapies really toxic for children? A study from eastern India. J AIDS HIV Res. 2012;4(9):219–22.

40. Tukei VJ, Asimwe A, Maganda A, Atugonza R, Sebuliba I, Bakeera-Kitaka S, et al. Safety and tolerability of antiretroviral therapy among HIV-infected children and adolescents in Uganda. J Acquir Immune Defic Syndr. 2012;59(3):274–80.

41. Ethiopian Federal Ministry of Health, National Guideline for comprehensive HIV prevention, care and treatment [Internet]. 2014. Available from: https://childrenandaids.org/sites/default/files/2017-05/Ethiopia-Consolidated-ART-Guideline-2014.pdf.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions